EMA guideline: no way...: [Design Issues]

posted by mittyri – Russia, 2019-12-07 19:58 (500 d 06:26 ago) – Posting: # 20959
Views: 3,898

Dear Osama,

» I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

I doubt that something exists at the moment.
Please also see the related discussion and cites of EMA guideline.

Kind regards,
Mittyri

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 14 (0 registered, 14 guests [including 4 identified bots]).
Forum time: Wednesday 02:25 UTC (Europe/Vienna)

In the Middles Ages the lingua franca of science was Latin.
Nowadays the language of science is bad English.    Anonymous

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5